Loading…
Loading…
Glenview Trust Co purchased a new position in AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 421,257 shares of the company's stock, valued at approximately $91,619,000. A number of other hedge funds and other institutional
Dearborn Partners LLC acquired a new position in shares of AbbVie Inc. (NYSE: ABBV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 128,402 shares of the company's stock, valued at approximately $27,926,000. AbbVie comprises about 1.3%
Empowered Funds LLC reduced its position in AbbVie Inc. (NYSE: ABBV) by 10.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 202,359 shares of the company's stock after selling 24,477 shares during the period. Empowered Funds LLC's holdings
BNP Paribas lifted its position in AbbVie Inc. (NYSE: ABBV) by 16.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,596 shares of the company's stock after buying an additional 11,318 shares during the period. BNP Paribas' holdings
Braun Stacey Associates Inc. raised its holdings in AbbVie Inc. (NYSE: ABBV) by 3.9% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 87,528 shares of the company's stock after purchasing an additional 3,269 shares during the quarter. Braun Stacey Associates Inc.'s
Ferguson Wellman Capital Management Inc. increased its position in shares of AbbVie Inc. (NYSE: ABBV) by 1.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 656,778 shares of the company's stock after buying an additional 6,367 shares during the quarter. AbbVie
Fulcrum Asset Management LLP purchased a new stake in shares of AbbVie Inc. (NYSE: ABBV) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 8,198 shares of the company's stock, valued at approximately $2,085,000. A number of other large
Field and Main Bank purchased a new position in shares of AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,715 shares of the company's stock, valued at approximately $2,696,000. Other institutional investors and hedge funds